On second thought, the FDA figures it no longer needs to discuss Exelixis’ application for Cabometyx in neuroendocrine tumors ...
FDA's Patrizia Cavazzoni to retire as CDER chief in 2nd senior official's departure in span of weeks
The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
Matt McNally is rejoining Publicis. The ad exec has taken the global CEO post at Publicis Health, returning to a company ...
A review of the FDA’s drug approvals of 2024 shows that small companies loomed large—both in the sheer number of nods g | ...
BD is banging the drum for self-collection of cervical cancer screening samples again. | BD is banging the drum for ...
Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. | For nearly a decade, Eli Lilly has been operating a global capability center (GCC) in Bengaluru, India. Now, with ...
When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...
In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients ...
If innovative cancer therapies were the top launches to watch in 2024, this year’s high-profile biopharma debuts is slated to ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning ...
Mendaera has found a leader with deep medical robotics experience to lead its commercialization push. Eric Davidson has taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback